Fahrenheit

Fahrenheit Pharmaceutical, also known as Huashi Pharmaceutical Group, is a leading integrated pharmaceutical service provider based in China. The company offers a comprehensive suite of services across the drug development lifecycle, including preclinical CMC (Chemistry, Manufacturing, and Controls), clinical research solutions, and regulatory support for both innovative and generic drugs. With over 50,000 square meters of laboratory space across major Chinese hubs like Beijing and Shanghai, Fahrenheit serves as a critical bridge in the pharmaceutical value chain. The group has attracted significant investment from global firms such as OrbiMed and has positioned itself as a major player in the CRO and CDMO sectors, supporting the development of small molecules and complex biologics.